MarketInOut Stock Screener Log In | Sign Up

Cytokinetics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 11/20/2026
Cytokinetics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization7,192.23 mln
Float134 mln
Earnings Date03/02/2027

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

9.75
Highly suspicious

1-Year Forecast

109.42
Transformational upside

Relative Strength

52 / 100
In line with market

Pre-Tax Margin

-687%
Severely loss-making

ROE

157
Extraordinary

Business Description

Cytokinetics is a US-based drug development company focused on creating medicines that target muscle function to treat serious heart and muscle diseases. Its lead product, MYQORZO, is an approved oral treatment for a condition where the heart muscle becomes abnormally thick and obstructed, and the company has several other drugs in various stages of clinical testing that aim to address different forms of heart failure. Founded in 1997 and based in South San Francisco, Cytokinetics is working to build a portfolio of treatments for patients with few existing options.

Key Fundamentals

EPS-6.02
ROE157
RPS0.88
ROIC-100
ROA-49.33
Interest Cover-5.17
EBITDA, mln-627
EV / EBITDA-12.60
EV / EBIT-12.33
Revenue, mln113
EV / Revenue69.77

Quote Details

Last 50.78
Change -0.68 (-1.32%)
Open 51.27
Volume 1,424,256
Turnover 72,323,720
Average Volume 2,023,883

Financial Ratios

Pre-Tax Profit Margin-687
Current Ratio3.36
Price / Sales64.86

Financial Strength

Altman Z-Score-1.52
Piotroski F-Score 3 / 9
Beneish M-Score9.75
1-Year Target Price109.42
Short Ratio10.04
Short % of Float19.65

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -9.53% 38 / 100   
1 Month -18.53% 28 / 100   
2 Months -33.07% 25 / 100   
6 Months -34% 26 / 100   
1 Year -21.62% 31 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog